Loading
1 insider bought €85k of shares over the last 90 days, the latest by Cairns Craig D., filed 10 Aug 2026.
Transcat Inc: what insiders have been doing
Transcat Inc belongs to the Industry sector. Filings by its managers are published through SEC (Form 4). 11 insiders have disclosed 29 filings since 22 October 2025.
Both sides are active: 1 purchase worth €85k and 2 sales worth €582k, from 1 insider and 2 insiders respectively. The net balance comes to €496k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 senior executive. At €540k, the sale published on 3 September 2026 by Dominach Oksana S. is the largest of the period (0.075% of market cap).
Compared with its exchange (3,171 companies, median 24 filings), a count of 29 filings is above the norm. The full history, which starts in 2016, counts 35 purchases against 99 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 28 March 2026), the company reported revenue of 331.9 m USD and net income of 5.4 m USD.
The last insider purchase was made public on 10 August 2026, 74 days ago. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
352
Thresholds
n/a
Buy Volume
€984,152
35 ops. · all time
Sell Volume
€21M
99 ops. · all time
Who traded when
BuySaleCraig D. Cairns3 buys
Christopher P. Gillette1 sale
Oksana S. Dominach1 sale
Since the insiders bought
- -15.8%Entry US$95.39 · Close 16 Oct 2026 US$80.35
- +19.3%Entry US$76.53 · Close at T+365 US$91.30
- +19.3%Entry US$76.53 · Close at T+365 US$91.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,238 of 26,240 companies
35.7
score / 100
Value35
Quality37
FCF yld2.4%
Earn yld0.7%
EV/EBITDA24.3x
ROE1.2%
Gross mgn33%
Net mgn1.6%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$86.31
Analyst consensus
3 analysts2.00/5
US$95.00Target US$104.33(+21%)US$113.00
Income statement
RevenueUS$331.9M
Gross profitUS$108.3M33% margin
EBITDAUS$38.8M12% margin
Net incomeUS$5.4M1.0% margin
Valuation
PER (trailing)239.7x
PER (forward)39.8x
P/Book2.7x
Beta0.66
Balance sheet & cash
Market capUS$807.8M
Total debtUS$133.3M
Free Cash FlowUS$19.6M
Debt / Equity47%
Profitability & ownership
ROE1.2%
ROA2.2%
% insiders2.4%
% institutions104.9%
Last declaration on 10 September 2026
Declarations352 total
1,587 shares0Common Stock, $.50 par valueSEC:0000891839-26-000398:0
1,587 shares0Common Stock, $.50 par valueSEC:0000891839-26-000399:0
1,587 shares0Common Stock, $.50 par valueSEC:0000891839-26-000400:0
1,587 shares0Common Stock, $.50 par valueSEC:0000891839-26-000401:0
1,587 shares0Common Stock, $.50 par valueSEC:0000891839-26-000402:0
1,587 shares0Common Stock, $.50 par valueSEC:0000891839-26-000397:0
1,587 shares0Common Stock, $.50 par valueSEC:0000891839-26-000403:0
1,587 shares0Common Stock, $.50 par valueSEC:0000891839-26-000404:0
7,312 shares@ US$85.59580.075% mcap100.0% of flowCommon Stock, $.50 par valueSEC:0000891839-26-000386:0
10,000 shares@ US$26.270.032% mcap50.0% of flowCommon Stock, $.50 par valueSEC:0000891839-26-000364:0
2,688 shares@ US$97.760.032% mcap50.0% of flowCommon Stock, $.50 par valueSEC:0000891839-26-000364:1
504 shares@ US$94.23450.0057% mcap100.0% of flowCommon Stock, $.50 par valueSEC:0000891839-26-000354:0
1,050 shares@ US$93.9650.012% mcap40.0% of flowCommon Stock, $.50 par valueSEC:0000891839-26-000347:0
Canonical exit: 4 Nov 2026 (T+90)
335 shares@ US$76.450.0031% mcap100.0% of flowCommon Stock, $.50 par valueSEC:0000891839-26-000194:1
760 shares@ US$76.450.0071% mcap100.0% of flowCommon Stock, $.50 par valueSEC:0000891839-26-000193:1
1,719 shares0Common Stock, $.50 par valueSEC:0000891839-26-000193:0
759 shares0Common Stock, $.50 par valueSEC:0000891839-26-000194:0
2,500 shares0Common Stock, $.50 par valueSEC:0000891839-26-000110:0
1,186 shares0Common Stock, $.50 par valueSEC:0000891839-26-000110:2
524 shares0Common Stock, $.50 par valueSEC:0000891839-26-000109:2
524 shares@ US$71.3230.5% of flowCommon Stock, $.50 par valueSEC:0000891839-26-000110:3
1,500 shares0Common Stock, $.50 par valueSEC:0000891839-26-000109:0
725 shares0Common Stock, $.50 par valueSEC:0000891839-26-000111:2
1,000 shares0Common Stock, $.50 par valueSEC:0000891839-26-000111:0
743 shares@ US$72.9776.6% of flowCommon Stock, $.50 par valueSEC:0000891839-26-000109:1
25 of 352 declarations
About Transcat Inc
Transcat Inc. is a U.S.-based industrial services and test-and-measurement company listed on the Nasdaq Global Market under ticker TRNS, with headquarters in Rochester, New York, United States. Founded in 1964 in Ohio, the company evolved from an industrial-grade calibration tools manufacturer into a specialized provider of technical services and value-added measurement equipment. For French-speaking investors, Transcat fits a niche industrial profile at the intersection of calibration, compliance, and mission-critical equipment support.
The business is organized into two highly complementary operating segments: Service and Distribution. The Service segment is the strategic core of the model. It includes accredited calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting, validation, Computerized Maintenance Management System (CMMS) solutions, and pipette services. Transcat primarily serves highly regulated end markets, especially life sciences, including pharmaceuticals, biotechnology, medical devices, and other FDA-regulated businesses. It also serves industrial manufacturing, energy and utilities, oil and gas, chemical manufacturing, and FAA-regulated customers such as aerospace and defense.
Read moreShow less
The Distribution segment extends the offering through the sale and rental of professional-grade handheld test, measurement, and control instrumentation from approximately 400 brands. The company markets more than 75,000 instruments and adds value by calibrating products before shipment, which allows customers to put equipment into service immediately upon receipt. Additional offerings include equipment kitting, rentals, and used-equipment sales. This integration between distribution and calibration services creates a differentiated proposition and helps raise competitive barriers versus more narrowly focused peers.
Geographically, Transcat remains predominantly U.S.-anchored but has a broader North American and European footprint. Its service centers, client-based labs, mobile calibration units, and distribution locations span the United States, Puerto Rico, Canada, and Ireland. That network supports a recurring, proximity-based service model and deepens customer relationships in regulated industries.
Recent corporate developments reinforce the company’s acquisition-led growth strategy. In fiscal 2025 and into 2026, Transcat expanded through acquisitions including Martin Calibration and Becnel Rental Tools, followed by Essco Calibration Laboratory and SCM Metrology and Laboratories. The company also rebranded NEXA as Transcat Solutions, broadening its asset management and compliance-related capabilities for biopharmaceutical customers. Overall, Transcat’s profile is that of a disciplined industrial compounder with recurring service revenue, technical expertise, and a consolidation strategy in fragmented, compliance-intensive markets.
